MAP4K5

Across TCGA pan-cancer cohorts, MAP4K5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP4K5 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAP4K5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP4K5 expression acts as an unfavorable survival marker.

HNSC, LIHC, and PRAD are the cancer types where MAP4K5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.142	0.626	.007	12	view →
LIHC	OS	Median	III,IV	0.093	0.649	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.209	0.682	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP4K5–HNSC (DFS)

Open the HNSC breakdown →